Study Identifies Processes in the Gut that Drive Fat Build-Up Around the Waist
Breakthrough research of faecal metabolites could lead to personalized obesity treatments within a decade
Breakthrough research of faecal metabolites could lead to personalized obesity treatments within a decade
Tested on human blood in the lab, the selective nanocapsules could reduce the side effects of a major blood clot-dissolving drug, which include bleeding on the brain
Enhanced PureTarget portfolio replaces the need for multiple tests with single scalable solution for inherited disease screening
No dark room required; fluorescence observation can be performed anywhere.
Sino Biological can produce highly efficient antibodies in HEK293 and CHO cells in as fast as 2 weeks with 1,000+ Antibodies per batch.
The company’s most significant advance in chromatography since UPLC aims to accelerate scientific research and development
Explore how CLINICAL24 Ambassador, Dr. Vasiliki E. Kalodimou, is leveraging flow cytometry to revolutionize treatments with stem cells and regenerative medicine
Join us online, May 17th, to discover the latest developments in the fields of microbiology and infectious disease
Optimized performance in cooled flatbed electrophoresis like 1D SDS PAGE, 2D electrophoresis, IEF.
Scientists identified 16 genes linked to rheumatoid arthritis, including key immune checkpoints, opening the door to precision treatments and potential cures
Safedevelop fingerprint development chambers are designed to safely develop latent fingerprints on porous surfaces using DFO, Ninhydrin, and other chemicals in a controlled environment for optimum effectiveness and safety where moisture, temperature, and development time are critical factors.
Unlock the full potential of the BD FACSymphony™ platform with the flexibility of spectral unmixing or compensation workflows
Almac Xcel™ Array for the profiling of FFPE samples provides the only 3’ gene expression array designed and optimized for use with formalin-fixed, paraffin-embedded (FFPE) tissues.
Bioxytran’s drug candidate, PHM23, utilizes a novel mechanism of action that targets galectin proteins critical to viral replication